Results 61 to 70 of about 530,731 (290)

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

Advanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li, Li Sun, Xiaoyu Pan, Shuyi Lin, Dongliang Wang, Jianping Zhang, Fengshuang Qiu, Bin Zhu, Lingzhou Zhao, Fengsheng Zhang, Liyan Bai, Bingxin Gu, Xiaoping Xu, Shaoli Song   +13 more
wiley   +1 more source

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

mAbs
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.
Alyssa Synan, Nila C. Wu, Roberto Velazquez, Thomas Gesner, Claude Logel, Kathrin Mueller, Andrew Green, Patrizia Barzaghi-Rinaudo, Quincey Simmons, Samuele Mercan, Xingyi Shi, Xun Li, Vivek Sagar, Joshua Korn, Margaret McLaughlin, William R. Tschantz, Dominik Hainzl, Anthony Malamas, Thomas Huber, Regis Cebe, Kathleen T. Xie, Joseph A. D’Alessio   +21 more
doaj   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing

Advanced Science, EarlyView.
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu, Xiyan Wang, Xiaozhen Liu, Chaoqi He, Da Qian, Xuli Meng, Liquan Zhu   +6 more
wiley   +1 more source

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

Nature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku, Xuping Xie, Jianqing Lin, Peng Gao, Bin Wu, Abbas El Sahili, Hang Su, Yang Liu, Xiaohua Ye, Eddie Yongjun Tan, Xin Li, Xuejun Fan, Boon Chong Goh, Wei Xiong, Hannah Boyd, Antonio E. Muruato, Hui Deng, Hongjie Xia, Jing Zou, Birte K. Kalveram, Vineet D. Menachery, Ningyan Zhang, Julien Lescar, Pei-Yong Shi, Zhiqiang An   +24 more
doaj   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

Advanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He, Xiao Lu, Chang qing Yang, Ran Zhang, Bo Wan, Xin Ni, Dong Mei   +6 more
wiley   +1 more source

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

Development of Bispecific Antibody Derivatives for Cancer Immunotherapy

, 2018
Development of antibody-based immunotherapeutics has progressed from direct tumor-targeting, with antibodies such as rituximab, to blocking of immune checkpoints to reactivate antitumor immunity.
Helfrich, Wijnand, Edwin Bremer, Bremer, Edwin, He, Yuan, Bremer, Edwin; id_orcid, Yuan He, Wijnand Helfrich   +6 more
core   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang, Yanlei Zhang, Shuixiu Peng, Chenchen Hou, Huaqi Guo, Tianyu Zhou, Alex H. Chang, Lifeng Yan, Weining Xiong   +8 more
wiley   +1 more source

Development and Evaluation of a Bispecific Single-Chain Antibody Targeting PSMA and CD3 to Enhance T-Cell-Mediated Lysis

American Journal of Men's Health
Prostate cancer is among the most prevalent malignancies in men worldwide and is associated with poor outcomes in advanced stages. Conventional therapies, including androgen deprivation and chemotherapy, provide limited benefit and are often accompanied ...
Mustafa Abdulkareem Aljaberi, Elyes Chabchoub   +1 more
doaj   +1 more source